Source: Dnake (Xiamen) Intelligent Technology Co., Ltd.

Source

HANGZHOU, China, Dec. 3, 2025 /PRNewswire/ — Against the backdrop of the accelerated upgrading of the global functional nutrition industry, technology-driven ingredient enterprises are increasingly emerging as the core force of the industrial chain. In November 2025, the FTA (Food Research Exchange Super Ingredients Conference) was successfully held in Hangzhou, gathering renowned enterprises from the fields of functional foods, nutritional ingredients, and innovative technologies to jointly showcase the latest industry trends. Among them, Natural Field, a company with years of experience in plant active substances and liposome delivery technology, collectively released a series of scientifically significant achievements with industry strategic value. It also won important awards at the conference for its multiple co-loading liposome products, establishing itself as one of the most watched upstream innovative enterprises at this year’s event.

During the conference, Natural Field conducted in-depth exchanges with industry experts, research institutions, and brand enterprises around hot topics such as “adaptogen”, “standardization of plant active substances,” and “liposome delivery systems.” The company not only announced the white paper and multiple technical data achievements but also demonstrated the latest progress in product R&D, platform technology construction, and industrial application implementation, reflecting its forward-looking layout and comprehensive strength in driving technological innovation in the functional nutrition sector.

At the main forum of the conference, Mr. Yang Haiying, founder of Natural Field, officially released the “Ashwagandha White Paper on”. As the first domestic enterprise to publish a comprehensive document on ashwagandha, Natural Field systematically sorted out the structural characteristics, mechanism of action, market trends, and product application logic of ashwagandha’s active ingredients in the white paper. Speaking at the launch, Mr. Yang stated that the adaptogen concept has entered a stage of rapid development in the global market, but there are still discrepancies in the industry’s understanding of its mechanisms, standardization, and raw material authenticity. Therefore, systematic research and data collation are crucial to ensuring the healthy development of the market. The release of the white paper attracted great attention from research institutions, brand owners, and R&D engineers, with many participants praising it as “the most systematic professional document on ashwagandha from a scientific research perspective in China.”

In addition to the research achievements in the adaptogen field, Natural Field’s progress in liposome technology became a key technical highlight of the conference. At the liposome technology sub-forum, Dr. Duan, leader of the innovative preparation research on co-loaded liposomes at Natural Field, delivered a professional speech, detailing the company’s latest research results in liposome and co-loaded liposome technologies. His speech focused on three major challenges commonly faced by functional nutrition products in oral applications: insufficient stability, low absorption efficiency limiting efficacy, and difficulty in achieving synergistic delivery of multiple ingredients. By presenting experimental data on co-loaded liposomes for Coenzyme Q10, curcumin, and other ingredients, Dr. Duan demonstrated that through structural encapsulation design, intermolecular synergistic configuration, and liposome morphology optimization, the metabolic pathway of ingredients in the human body can be significantly improved, bioavailability enhanced, and functional performance strengthened in certain inflammatory models.

Notably, Natural Field also disclosed data on the performance of some co-loading liposomes in myocarditis and intestinal inflammation models during the presentation. These data highlighted the advantages of co-loading technology in synergistic stability, consistent efficacy, and in vivo distribution of multiple ingredients, triggering intense discussions among on-site technical personnel. After the forum, leaders from multiple participating brand enterprises communicated with Natural Field, expressing intentions to cooperate in product development, technical verification, and ingredient combination design.

Leveraging its solid scientific research strength and technical achievements, Natural Field’s raw material products won awards at this year’s Very Food Innovation Conference. Its NF Co-loading® Liposomal Coenzyme Q10 (raw material) received the “Cardiovascular Health Award” in recognition of its technical breakthroughs in stability, absorption efficiency, and process maturity. Meanwhile, NF Co-loading® Liposomal Coenzyme Q10 (finished capsule product) won the “Potential New Product Award” for its excellent application implementation capabilities. Additionally, the company’s previously developed NF Co-loading® Liposomal Curcumin had already been awarded the Gold Award for Innovation in Natural Ingredients at the 2025 CPHI, further solidifying its technical position in co-loaded liposome technology in the international market.

Beyond showcasing core scientific research achievements, Natural Field also systematically presented its “one-stop liposome service platform” to the industry during the conference. Based on years of experience in functional ingredient research, the company has established a full-process platform system covering raw material screening, liposome encapsulation design, co-loading technology development, stability test verification, efficacy model research, and finished product application support. This platform not only provides domestic brand enterprises with systematic technical support from raw materials to finished products but also attracted technical cooperation intentions from brands in Europe, America, Japan, and other regions. Industry experts commented that a company truly capable of integrating plant active substance research with delivery system construction will become a crucial ecological player in the future competition of the functional nutrition industry.

Natural Field stated that it will continue to conduct in-depth research on key technical issues in the functional nutrition industry and plans to release new data on multiple ingredient synergistic delivery, liposome structure optimization, and application stability research in the coming year. In the future, the company will continue to participate in major domestic and international industry exhibitions, maintain technical exchanges with global research teams and nutrition brands, and jointly promote the industry towards a more scientific, efficient, and safe direction.

As innovative technology plays an increasingly important role in the functional nutrition industry, Natural Field’s concentrated release at the Very Food Innovation Conference marks the industry’s transition from “raw material competition” to “technology competition.” Through continuous scientific research investment and technical integration capabilities, Natural Field is becoming a key driving force in advancing the industry into the era of efficient delivery.

Source

SHANGHAI and HONG KONG, Dec. 2, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), as well as ATG-022 in combination with pembrolizumab and chemotherapy.

CLINCH-2 is a Phase Ib/II study that will be led by its principal investigator Prof. Lin Shen at Beijing Cancer Hospital, the lead trial center. The study is designed to evaluate two combination regimens in patients with CLDN18.2-positive, HER2-negative, and PD-L1-positive (CPS≥1) unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJC): ATG-022 in combination with pembrolizumab (A+P); and ATG-022 in combination with pembrolizumab plus the CAPOX chemotherapy regimen (A+P+C). The primary objective of the study is to assess the safety and tolerability of the two combination regimens, while the secondary objectives include evaluating the regimens’ preliminary antitumor activity, assessing ATG-022’s immunogenicity, and characterizing its pharmacokinetic (PK) profile.

Antengene released updated clinical data from the Phase I/II CLINCH study of ATG-022 monotherapy in patients with advanced GC/GEJC at the European Society for Medical Oncology Congress 2025 (ESMO 2025). For details of the dataset, please refer to the press release published on October 20, 2025 (https://www.antengene.com/newsinfo/449). The results demonstrated clear differentiation for ATG-022 in both safety and efficacy. In the 1.8 mg/kg dose cohort, the incidence of grade 3 or higher treatment-related adverse events was only 18.2%. Moreover, the study did not observe any ocular toxicity or interstitial lung disease, and the incidence of peripheral neuropathy reported in the study was relatively low. The efficacious doses (1.8mg/kg and 2.4mg/kg) have both demonstrated an objective response rate (ORR) of 40%. This is a strong validation of ATG-022’s potential in combination with pembrolizumab and chemotherapy in the frontline setting. In addition, antitumor activity was observed across high, medium, and low CLDN18.2 expression levels, supporting the use of IHC 1+ ≥1% as the enrollment threshold for frontline combination therapy, indicating potential applicability to a much broader patient population compared to other CLDN18.2-targeting therapies. Furthermore, in the basket cohort of other CLDN18.2+ tumor types, efficacy was observed in a gynecologic tumor subtype, providing early proof of concept for potential expansion into tumor types beyond gastric cancer.

Antengene will continue to advance both the ongoing CLINCH study and the newly approved CLINCH-2 study, with plans to share updated results at upcoming medical conferences to further demonstrate the clinical potential of ATG-022.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

About ATG-022

ATG-022 is a CLDN18.2-targeted antibody-drug conjugate (ADC) with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload (DAR 4), ATG-022 has demonstrated potent activity across tumors with high, low, and ultra-low CLDN18.2 expression.

ATG-022 has been granted two Orphan Drug designations (ODDs) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer, and obtained Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA) for treating CLDN18.2-positive, HER-2 negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received at least two prior lines of therapy.

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com 

Source

ABU DHABI, UAE, Dec. 1, 2025 /PRNewswire/ — The Abu Dhabi Film Commission (ADFC), part of the Creative Media Authority (CMA), has unveiled a new behind-the-scenes video showcasing how Lionsgate’s Now You See Me: Now You Don’t was filmed in the UAE capital, marking another major Hollywood production successfully delivered in Abu Dhabi. The feature highlights the extensive collaboration between Creative Media Authority, Abu Dhabi Film Commission, Miral Destinations and local production services provider Epic Films, demonstrating how Abu Dhabi’s world class production offering and integrated film ecosystem are attracting global studios to the region. The film, now in worldwide release, took in over $80.5 million in its opening weekend.

The video offers an inside look at how Abu Dhabi’s collaborative government framework, streamlined production support and advanced infrastructure made it possible to complete this large-scale international shoot.

A crew of more than 450 professionals, including 290 international crew members and over 170 local freelancers from Abu Dhabi’s expanding creative sector, contributed to the project, underscoring the capital’s deepening pool of technical and creative talent capable of delivering world class results.

The footage reveals the scale and ambition of the Abu Dhabi shoot, featuring interviews with director Reuben Fleischer, producer Bobby Cohen, EVP Physical Production Kelly Konop and production designer David Scheunemann.

The Abu Dhabi production was supported by CMA through the ADFC’s 35%++ cashback rebate, streamlined permitting and on-ground facilitation, delivered in close coordination with local production services provider Epic films, Miral destinations for key locations as well as industry partners and government entities across the emirate.

Sameer Al Jaberi, Head of Abu Dhabi Film Commission, said: “This behind-the-scenes film celebrates the collaborative ecosystem that makes Abu Dhabi a truly film-friendly destination. Completing a production of this scale showcases our efficiency, strong inter-agency coordination, and the talent within our local creative media industry. It’s a powerful example of how Abu Dhabi enables international filmmakers to bring their vision to life while contributing to the growth of our creative ecosystem.”

Liam Findlay, Chief Executive Officer of Miral Destinations, said: “Our collaboration with the Abu Dhabi Film Commission, Creative Media Authority and Lionsgate on this production highlights Yas Island and wider Abu Dhabi as a world-class destination for filmmakers. From Yas Island’s iconic architecture and attractions to Abu Dhabi’s supportive framework, we continue to set the stage for globally acclaimed storytelling and cinematic innovation.” 

The production underscores Abu Dhabi’s status as an internationally renowned hub for cinematic storytelling. The Abu Dhabi Film Commission has supported more than 180 large-scale film and television projects, including Mission: Impossible – Dead Reckoning Part One, Dune: Part Two, and F1: The Movie. With its seamless production support, advanced facilities and cinematic diversity, Abu Dhabi continues to strengthen its position as one of the world’s leading film production destinations.

Now You See Me: Now You Don’t is now showing in cinemas worldwide.

Now You See Me: Now You Don’t – Behind the scenes shot in Abu Dhabi

Now You See Me: Now You Don’t – Behind the scenes shot in Abu Dhabi

Source

– To be held over three days from the 2nd to the 4th in Paris, France, with 1,550 companies and more than 24,000 visitors expected.

– Specialty ingredients including amino acids and microalgae to be showcased, along with tasting sessions featuring dishes made with the natural seasoning ingredient “Dsavory”

SEOUL, South Korea, Dec. 1, 2025 /PRNewswire/ — Daesang will participate in “FiE 2025 (Food Ingredients Europe 2025),” one of the world’s largest food ingredient exhibitions, to be held in Paris, France from the 2nd to the 4^th. The company’s participation reflects its commitment to expand its global ingredient business capabilities and strengthen its presence in the international market.

Launched in 1986, Food Ingredients Europe (FiE) is the largest food and food additive exhibition in Europe, showcasing the latest technologies and trends in food ingredients and additives. It serves as a global platform to explore essential raw materials and additives for food manufacturing, as well as the latest trends in the food industry. This year, more than 1,550 companies from approximately 135 countries and over 24,000 visitors, including professional buyers, are expected to attend.

At the exhibition, Daesang will showcase three categories of specialty high-performance ingredients, including natural seasoning ingredients, EMULAID, and microalgae, backed by its proprietary technologies developed through years of experience in the domestic and global food ingredient business. By introducing its extensive ingredient portfolio developed through long-standing fermentation expertise, the company aims to expand its overseas sales channels and strengthen partnerships with global clients to reinforce its position in the global ingredient market.

Daesang will introduce the natural seasoning ingredient “Dsavory,” which enhances natural umami while preserving the original taste of food. Dsavory enables balanced umami across a wide range of products and delivers deep flavor without using actual meat, making it applicable to soups, snacks, and alternative proteins, while supporting environmentally friendly and sustainable product development. At this year’s exhibition, Daesang will also operate a tasting session where visitors can sample nuggets and soups made with Dsavory ingredients.

Six high value amino acids including L-arginine, L-glutamine, and L-citrulline will also be exhibited. These ingredients are widely used in pharmaceuticals, health functional foods, and animal feed, and global demand continues to grow as they serve as core raw materials for nutritional fortification and functional product development.

The company will also introduce plant based protein ingredients derived from microalgae, including Green Chlorella, GoldRella, and White Chlorella. These ingredients contain protein and dietary fiber, as well as essential amino acids, vitamins, and minerals, making them suitable for plant based alternative foods and health functional foods. Their safety and regulatory compliance are supported by SA-GRAS (Self-Affirmed Generally Recognized as Safe) status, which authorizes their use and sale in the United States.

In addition, Daesang will introduce the modified starch “EMULAID,” which stabilizes texture and flavor by preventing the separation of oil and water. Made from waxy corn starch, it is suitable for vegan applications, has low viscosity, and dissolves easily even in cold water, enabling its use in across a wide range of manufacturing processes.

Lee Hyo-hoon, Head of Ingredient Marketing at Daesang, said, “This global ingredient exhibition offers an important opportunity to showcase the strength of Daesang’s specialty ingredients developed through our proprietary technologies, while gaining insight into evolving trends and expanding our international network. We will continue to strengthen cooperation with our global clients based on our unique expertise and technologies to broaden our presence on the worldwide ingredient market.”

About Daesang Corporation
Founded in 1956, Daesang Corporation has been one of the world’s largest producers of fermented food products for over 60 years, and has grown to be the global leading Korean based food company by operating global brands such as Jongga, and O’Food which provides sauce, ready-to-eat meals, and many more products. Headquartered in South Korea, the company also has manufacturing subsidiaries in United States, Poland, China, Indonesia, and Vietnam. Visit www.daesang.com/en for more information.

Source